CEO Tom Frohlich was paid $9,799,759 in fiscal year 2025, ↑ up 618.2% from fiscal year 2024, the 88th percentile of its disclosed peer group (SEC filing 0001193125-26-187059 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$9,799,759 ↑ Tom Frohlich total, FY2025 | 88th CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
JBIO's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Tom Frohlich | $621,970 | $0 | $0 | $8,779,876 | $397,913 | $0 | $0 | $9,799,759 |
| Chief Executive Officer, President and Director | ||||||||
| Andrew King | 507,301 | 0 | 0 | 3,775,903 | 258,600 | 0 | 0 | 4,541,804 |
| President, Research and Development | ||||||||
| Bradford Dahms | 233,013 | 0 | 0 | 3,781,940 | 113,600 | 0 | 3,438 | 4,131,991 |
| Chief Financial Officer | ||||||||
| Timothy Noyes | 213,767 | 0 | 0 | 0 | 0 | 0 | 1,600,716 | 1,814,483 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Tom Frohlich | $9,799,759 | $1,364,396 | — | ↑ +8,435,363 |
| Andrew King | 4,541,804 | 751,605 | — | ↑ +3,790,199 |
| Bradford Dahms | 4,131,991 | — | — | — |
| Timothy Noyes | 1,814,483 | 3,391,536 | 3,070,657 | ↓ −1,577,053 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Jade Biosciences, Inc.'s Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper JBIO reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses JBIO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named JBIO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Allison Dorval | Former director (through FY2025) | $25,000 |
| Chris Cain | Independent Director | $205,672 |
| Christopher Cain, Ph.D | Independent Director | $205,672 |
| David Grayzel, M.D | Former director (through FY2025) | $10,750 |
| Donald J. Santel | Former director (through FY2025) | $9,750 |
| Eric Dobmeier, J.D | Independent Director | $226,935 |
| Erin Lavelle | Independent Director | $212,422 |
| Habib J. Dable | Former director (through FY2025) | $21,250 |
| Joshua Resnick, M.D | Former director (through FY2025) | $19,500 |
| Lawrence Klein, Ph.D | Independent Director | $210,059 |
| Mark Iwicki | Former director (through FY2025) | $26,250 |
| Tomas Kiselak | Independent Director | $206,347 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Andrew King | RSU | 229,907 | — | $3,547,465 |
| Tom Frohlich | Option | 817,643 | 6.03 | — |
| Tom Frohlich | Option | 779,934 | 6.03 | — |
| Tom Frohlich | Option | 659,550 | 0.96 | — |
| Andrew King | Option | 184,147 | 6.03 | — |
| Bradford Dahms | Option | 526,000 | 9 | — |
| Andrew King | RSU | 8,625 | — | 133,084 |
| Andrew King | Option | 552,709 | 6.03 | — |
| Andrew King | Option | 123,600 | 1.46 | — |
The primary elements of compensation for our NEOs are base salary, annual bonuses and long-term incentive awards in the form of equity awards. The compensation program is weighted toward long-term incentive compensation to discourage short-term risk taking.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | — | — | — | — | — |
| 2024 | 2024-06-05 | — | — | — | — | — |
| 2023 | 2023-06-06 | — | — | — | — | — |
| 2022 | 2022-06-21 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-09 | —a |
| 2024 | 2024-06-05 | —b |
| 2023 | 2023-06-06 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Eric Dobmeier, J.DIndependent · Audit · Nominating and Corporate Governance | $55,688 | — | $171,247 | — | $0 | $226,935 |
| Erin LavelleIndependent · Audit (Chair) · Compensation | 41,175 | — | 171,247 | — | 0 | 212,422 |
| Lawrence Klein, Ph.DIndependent · Audit · Nominating and Corporate Governance (Chair) | 38,812 | — | 171,247 | — | 0 | 210,059 |
| Tomas KiselakIndependent · Compensation (Chair) | 35,100 | — | 171,247 | — | 0 | 206,347 |
| Chris CainIndependent | 34,425 | — | 171,247 | — | 0 | 205,672 |
| Christopher Cain, Ph.DIndependent · Compensation · Nominating and Corporate Governance | 34,425 | — | 171,247 | — | 0 | 205,672 |
| Mark IwickiIndependent · Departed during FY | 26,250 | — | 0 | — | 0 | 26,250 |
| Allison DorvalIndependent · Departed during FY | 25,000 | — | 0 | — | 0 | 25,000 |
| Habib J. DableIndependent · Departed during FY | 21,250 | — | 0 | — | 0 | 21,250 |
| Joshua Resnick, M.DIndependent · Departed during FY | 19,500 | — | 0 | — | 0 | 19,500 |
| David Grayzel, M.DIndependent · Departed during FY | 10,750 | — | 0 | — | 0 | 10,750 |
| Donald J. SantelIndependent · Departed during FY | 9,750 | — | 0 | — | 0 | 9,750 |
| Tom FrohlichEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $35,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $352,125 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $352,125 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Jade Biosciences, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Jade Biosciences, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Janux Therapeutics, Inc. | 2025 | David Campbell | $680,000 | $0 | $12,459,031 | $367,200 | $13,506,231 |
| 2 | Dianthus Therapeutics, Inc. | 2025 | Marino Garcia | 630,000 | 0 | 9,450,952 | 519,750 | 10,614,702 |
| 3 | Jade Biosciences, Inc. | 2025 | Tom Frohlich | 621,970 | 0 | 8,779,876 | 397,913 | 9,799,759 |
| 4 | CARGO Therapeutics, Inc. | 2024 | Gina Chapman | 630,800 | 0 | 8,155,520 | 363,800 | 9,300,120 |
| 5 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 6 | Spyre Therapeutics, Inc. | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 7 | Astria Therapeutics, Inc. | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 8 | Alumis Inc. | 2025 | Martin Babler | 680,830 | 0 | 4,743,220 | 524,239 | 5,948,289 |
| 9 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 10 | Zenas BioPharma, Inc. | 2025 | Leon Moulder | 520,000 | 0 | 3,769,200 | 371,800 | 4,661,000 |
| 11 | Upstream Bio, Inc. | 2025 | E. Rand Sutherland | 650,000 | 0 | 3,300,350 | 341,250 | 4,302,100 |
| 12 | Lyell Immunopharma, Inc. | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 13 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 14 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 15 | Contineum Therapeutics, Inc. | 2025 | Carmine Stengone | 655,620 | 0 | 2,291,640 | 450,739 | 3,409,448 |
| 16 | Oruka Therapeutics, Inc. | 2025 | Lawrence Klein | 624,000 | 0 | 2,275,390 | 446,160 | 3,356,050 |
| 17 | Kyverna Therapeutics, Inc. | 2025 | Warner Biddle | 625,000 | 0 | 543,804 | 468,750 | 1,814,980 |
| 18 | Apogee Therapeutics, Inc. | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
| — | ACELYRIN, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Third Harmonic Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Jade Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| ACELYRIN, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Alumis Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Apogee Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Astria Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| CARGO Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Contineum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Alpine |
| Dianthus Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Entrada Therapeutics, Inc. | not disclosed | not disclosed | No | Pay Governance |
| Janux Therapeutics, Inc. | 90% | not disclosed | not disclosed | FW Cook |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Kyverna Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon plc |
| Lyell Immunopharma, Inc. | 100% | not disclosed | No | Alpine |
| Oruka Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards LLC |
| Pliant Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Prime Medicine, Inc. | 120% | not disclosed | not disclosed | Alpine Rewards |
| Spyre Therapeutics, Inc. | 130% | Option 100 | not disclosed | Alpine Rewards |
| Third Harmonic Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Upstream Bio, Inc. | 52.5% | Option 100 | not disclosed | Alpine Rewards |
| Zenas BioPharma, Inc. | not disclosed | Option 100 | not disclosed | Alpine |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Tom Frohlich | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 9,799,759. Filing ↗machine: r2 · c23 · span 401361–401370 |
| 2 | Section 01, Andrew King | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 4,541,804. Filing ↗machine: r4 · c23 · span 406661–406670 |
| 3 | Section 01, Bradford Dahms | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 4,131,991. Filing ↗machine: r6 · c23 · span 411876–411885 |
| 4 | Section 01, Timothy Noyes | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “SUMMARY COMPENSATION TABLE”. As printed: 1,814,483. Filing ↗machine: r8 · c23 · span 416137–416146 |
| 5 | Section 08, Eric Dobmeier, J.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 226,935. Filing ↗machine: span 544321–544377 |
| 6 | Section 08, Erin Lavelle | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 212,422. Filing ↗machine: span 552928–552984 |
| 7 | Section 08, Lawrence Klein, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 210,059. Filing ↗machine: span 550755–550811 |
| 8 | Section 08, Tomas Kiselak | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 206,347. Filing ↗machine: span 548623–548679 |
| 9 | Section 08, Chris Cain | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 205,672. Filing ↗machine: span 546449–546505 |
| 10 | Section 08, Christopher Cain, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 205,672. Filing ↗ |
| 11 | Section 08, Mark Iwicki | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 26,250. Filing ↗machine: span 560504–560545 |
| 12 | Section 08, Allison Dorval | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 25,000. Filing ↗machine: span 556064–556105 |
| 13 | Section 08, Habib J. Dable | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 21,250. Filing ↗machine: span 553847–553888 |
| 14 | Section 08, Joshua Resnick, M.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 19,500. Filing ↗machine: span 562731–562772 |
| 15 | Section 08, David Grayzel, M.D | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 10,750. Filing ↗machine: span 558290–558331 |
| 16 | Section 08, Donald J. Santel | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 9,750. Filing ↗machine: span 564950–564990 |
| 17 | Section 08, Tom Frohlich | DEF 14A | 2026-04-28 | 0001193125-26-187059 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 06, 2026 vote | Form 8-K | 2026-06-11 | 0001193125-26-267640 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 19 | Section 06, 2024 vote | Form 8-K | 2024-06-07 | 0001798749-24-000033 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 20 | Section 06, 2023 vote | Form 8-K | 2023-06-08 | 0001798749-23-000042 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 21 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 22 | Section 09b board cost (computed) | Computed | — | — | Cash 352,125 + equity 0 + all other 0 = 352,125, summed across the director compensation table rows.machine: formula: Σ = 352,125 |
| 23 | Janux Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187095 | CEO total compensation as printed in Janux Therapeutics, Inc.'s own proxy. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 24 | Dianthus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001690585-26-000012 | CEO total compensation as printed in Dianthus Therapeutics, Inc.'s own proxy. As printed: 10,614,702. Filing ↗machine: r2 · c25 · span 382326–382336 |
| 25 | Jade Biosciences, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187059 | CEO total compensation as printed in Jade Biosciences, Inc.'s own proxy. As printed: 9,799,759. Filing ↗machine: r2 · c23 · span 401361–401370 |
| 26 | CARGO Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001193125-25-103786 | CEO total compensation as printed in CARGO Therapeutics, Inc.'s own proxy. As printed: 9,300,120. Filing ↗machine: r2 · c31 · span 289578–289587 |
| 27 | Kymera Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 28 | Spyre Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001636282-26-000039 | CEO total compensation as printed in Spyre Therapeutics, Inc.'s own proxy. As printed: 6,707,361. Filing ↗machine: r2 · c48 · span 393018–393027 |
| 29 | Astria Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-28 | 0001104659-25-040180 | CEO total compensation as printed in Astria Therapeutics, Inc.'s own proxy. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460 |
| 30 | Alumis Inc., Section 10b CEO total | DEF 14A | 2026-05-18 | 0001104659-26-063223 | CEO total compensation as printed in Alumis Inc.'s own proxy. As printed: 5,948,289. Filing ↗machine: r1 · c29 · span 406891–406900 |
| 31 | Pliant Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 32 | Zenas BioPharma, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001104659-26-028062 | CEO total compensation as printed in Zenas BioPharma, Inc.'s own proxy. As printed: 4,661,000. Filing ↗machine: r1 · c41 · span 360346–360355 |
| 33 | Upstream Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-158966 | CEO total compensation as printed in Upstream Bio, Inc.'s own proxy. As printed: 4,302,100. Filing ↗machine: r2 · c24 · span 433625–433634 |
| 34 | Lyell Immunopharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016686 | CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. Filing ↗machine: r2 · c24 · span 450163–450172 |
| 35 | Prime Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026697 | CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188 |
| 36 | Entrada Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001689375-26-000021 | CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900 |
| 37 | Contineum Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028881 | CEO total compensation as printed in Contineum Therapeutics, Inc.'s own proxy. As printed: 3,409,448. Filing ↗machine: span 271162–271171 |
| 38 | Oruka Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001213900-26-045159 | CEO total compensation as printed in Oruka Therapeutics, Inc.'s own proxy. As printed: 3,356,050. Filing ↗machine: r1 · c12 · span 534154–534163 |
| 39 | Kyverna Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001193125-26-152835 | CEO total compensation as printed in Kyverna Therapeutics, Inc.'s own proxy. As printed: 1,814,980. Filing ↗machine: r2 · c26 · span 547940–547949 |
| 40 | Apogee Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177342 | CEO total compensation as printed in Apogee Therapeutics, Inc.'s own proxy. As printed: 1,291,500. Filing ↗ |
| 41 | Section 10a, Janux Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-187095 | Janux Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 42 | Section 10a, Contineum Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-26-028881 | Contineum Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 43 | Section 10a, Lyell Immunopharma, Inc. reciprocity | DEF 14A | — | 0001140361-24-021008 | Lyell Immunopharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 44 | Section 10a, Astria Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040180 | Astria Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 45 | Section 10a, Apogee Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177342 | Apogee Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 46 | Section 10a, Oruka Therapeutics, Inc. reciprocity | DEF 14A | — | 0001213900-26-045159 | Oruka Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 47 | Section 10a, Dianthus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001690585-26-000012 | Dianthus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 48 | Section 10a, Pliant Therapeutics, Inc. reciprocity | DEF 14A | — | 0001746473-26-000076 | Pliant Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 49 | Section 10a, Kymera Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |
| 50 | Section 10a, Spyre Therapeutics, Inc. reciprocity | DEF 14A | — | 0001636282-26-000039 | Spyre Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Jade Biosciences, Inc.. Filing ↗ |